Published in Anti-Infectives Week, April 12th, 2004
Cubicin (daptomycin for injection), a first in class bactericidal antibiotic, was launched in the U.S. by Cubist in late 2003 for the treatment of complicated skin and skin structure infections caused by certain Gram-positive organisms.
Cubicin is currently the only once-daily bactericidal antibiotic proven effective against both methicillin-resistant and methicillin-susceptible Staphylococcus aureus (MRSA and MSSA).
Debra Goff, PharmD, clinical associate professor, and infectious diseases specialist at...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.